NCT03629886View on ClinicalTrials.gov

Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study

PHASE4CompletedINTERVENTIONAL
Enrollment

6,051

Participants

Timeline

Start Date

August 22, 2018

Primary Completion Date

February 28, 2020

Study Completion Date

February 28, 2020

Conditions
Cervical Intraepithelial Neoplasia
Interventions
BIOLOGICAL

HPV (Types 16, 18) Vaccine, Adsorbed

Three doses of Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed administered intramuscularly in the deltoid region of the upper arm, according to a 0, 1, 6-month schedule.

Trial Locations (4)

213200

GSK Investigational Site, Jintan

221006

GSK Investigational Site, Xuzhou

223400

GSK Investigational Site, Lianshui

224500

GSK Investigational Site, Yancheng

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT03629886 - Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study | Biotech Hunter | Biotech Hunter